Inventor · disambiguated record
Yoshinao Ruike
Also filed as: RUIKE YOSHINAO
13 granted patents·10 pending applications·151 citations·filing 2011–2024
92Inventor score
Top patents by PatentIndex Score
23 records- 0197US9765135B2Anti-C5 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Sep 19, 2017·51 cites·66 claims
- 0296US11454633B2Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Sep 27, 2022·4 cites·19 claims
- 0396US10738111B2Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Aug 11, 2020·17 cites·25 claims
- 0496US10000560B2Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Jun 19, 2018·26 cites·43 claims
- 0594US11597760B2Method of detecting the presence of complement C5CHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted Mar 7, 2023·6 cites·10 claims
- 0694US10385122B2Nucleic acids encoding anti-C5 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Aug 20, 2019·14 cites·58 claims
- 0794US10023630B2Methods of neutralizing C5 with anti-C5 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Jul 17, 2018·14 cites·70 claims
- 0893US11827699B2Methods for producing antibodies promoting disappearance of antigens having plurality of biological activitiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Nov 28, 2023·8 cites·20 claims
- 0991US11891434B2Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Feb 6, 2024·6 cites·32 claims
- 1087US2025076311A1Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 1186US11359009B2Anti-myostatin antibodies and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Granted Jun 14, 2022·5 cites·21 claims
- 1283US2024279325A1Antigen-binding molecule promoting disappearance of antigens having plurality of biological activitiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1382US2024052021A1Anti-c5 antibodies and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1478US2024158482A1Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1570US12252532B2Anti-myostatin antibodies and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Granted Mar 18, 2025·0 cites·6 claims
- 1668US2024239890A1Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1767US12169205B2Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Dec 17, 2024·0 cites·5 claims
- 1857US2015050269A1Antigen-binding molecule promoting disappearance of antigens having plurality of biological activitiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Application pending·0 cites
- 1955US2014234340A1Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedlyIGAWA TOMOYUKI·Filed 2011·Application pending·0 cites
- 2054US2017022270A1Antigen-binding molecule promoting disappearance of antigens having plurality of biological activitiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Application pending·0 cites
- 2152US2023383011A1Site specific notch-activating molecule and uses thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2248US2020123256A1Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Application pending·0 cites
- 2335US11827717B2Anti-MASP-1 antibodies and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Nov 28, 2023·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when Yoshinao Ruike files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →